Atlas Trials

A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D

Clinical trial NCT03546621 · COMPLETED

Trial details

NCT number
NCT03546621
Sponsor
Hepatera Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Hepatitis D Infection With Hepatitis B
Start date
2016-02-16
Primary completion
2018-01-31
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.